Business Context and Reporting Period
This Form 8-K is a current report filed by Hemispherx Biopharma, Inc. (not AIM Immunotech Inc.) on February 23, 2011, regarding events occurring on February 17, 2011. The filing addresses a compliance issue with the NYSE Amex regarding the timing of the Company's 2010 Annual Stockholders' Meeting.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance and corporate governance matters rather than financial performance data.
Material Changes and Events
- Delisting Notice: On February 17, 2011, the Company received notice from the NYSE Amex that it was not in compliance with Section 704 of the Amex Company Guide for failing to hold its 2010 Annual Stockholders' Meeting by December 31, 2010.
- Root Cause: The delay was caused by unanticipated SEC comments on the Company's 2009 Annual Report (Form 10-K). Final resolution of these accounting comments was not obtained until mid-February 2011.
- Corrective Actions: The Company filed an amended and restated 2009 10-K and amended 10-Q reports for the first three quarters of 2010. The Annual Meeting was rescheduled for March 17, 2011.
Outlook, Risks, and Management Commentary
Management plans to notify the NYSE Amex after the March 17, 2011 meeting that the requirement has been satisfied, thereby avoiding the need to submit a formal compliance plan. The filing explicitly states that if the Company fails to submit a plan by March 21, 2011, or if the meeting is not held/accepted, the Company will be subject to delisting procedures under Section 1010 and Part 12 of the Amex Company Guide.
Investor Verification Checklist
- Confirm the successful holding of the Annual Stockholders' Meeting on March 17, 2011.
- Verify the Company's continued listing status on the NYSE Amex following the March 21, 2011 deadline.
- Review the amended and restated 2009 Form 10-K and 2010 Form 10-Q filings to understand the nature of the SEC accounting comments.
- Monitor for any subsequent press releases regarding the resolution of the delisting notice.